Clinical Response of Nuberol Forte in Chronic Neck Pain in Routine Rehabilitation Centers
CompletedNCT06628466
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Globally, the prevalence of neck pain ranges from 16.7% to 75.1%. Despite conducting multiple studies on specific subject pools in Pakistan, primarily focusing on professional-related neck pain, there is a lack of accurate data to determine the local prevalence of neck pain or the effective management of neck pain through physical therapy and pharmacological intervention. The purpose of this study is to evaluate the clinical effectiveness of paracetamol and orphenadrine (Nuberol Forte) when combined with physical therapy in Pakistani patients suffering from neck pain at regular rehabilitation centers.
Study details
- Official title
- Clinical Response of Nuberol Forte in Chronic Neck Pain in Routine Rehabilitation Centers
- Conditions
- Interventions
- Drug: Nuberol Forte
- Sponsor
- The Searle Company Limited Pakistan
- Start date
- 2022-11-25
- Primary completion
- 2023-12-20
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Pakistan
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patient with a clinical history of chronic neck pain from last 3 months. * Patient aged ≥18 and ≤70 years inclusive of either sex. * Patient with ability to understand and sign written informed consent form. Exclusion Criteria: * Subjects with acute or subacute neck pain. * Subjects with specific etiology for neck pain (e.g. trauma, herniated disc, vertebral deformities, fractures); * Subjects with central or peripheral neurological signs. * Individuals with systemic diseases, neuromuscular diseases, rheumatic diseases, cognitive deficit, tumors. * Known hypersensitivity to Nuberol Forte product, the metabolites, or formulation excipients. * Patients with Glaucoma, prostatic hypertrophy or obstruction at the bladder neck, myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction. * Treated with Nuberol Forte to evaluate safety as per approved prescribing information for Nuberol Forte in Pakistan. * Pregnant (assesed on LMP) or breast feeding women (assessed on interview).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06628466